Status:
COMPLETED
Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
University Hospital, Gentofte, Copenhagen
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Both pre- and postconditioning seem to protect cardiomyocytes during reperfusion therapy. Investigations both ex vivo and in vivo suggest that a gut derived hormone, Glucagon-Like-Peptide-1 (GLP-1), i...
Eligibility Criteria
Inclusion
- More than 18 years of age.
- STEMI less than 12 hours from onset of pain. STEMI defined as as ST-segment elevation in 2 contiguous electrocardiographic leads of \>0.1 mV in V4 - V6 or limb leads II, III and aVF, or \>0.2 mV in lead V1 - V3.
- TIMI 0-1 in infarct related artery.
- Oral and written informed consent.
Exclusion
- Multivessel disease defined by one or more stenoses \>70% in diameter in the non infarct related artery.
- Previous myocardial infarction.
- Stent trombosis.
- Previous CABG.
- Less than TIMI 2 following wiring and predilatation of the infarct related artery but prior to postconditioning or placebo treatment.
- Renal insufficiency (creatinin \>200).
- Pregnancy or lactation.
- Diabetic ketoacidose eller hypoglycemia (plasma glukose \< 2.5 mmol/l).
- Pancreatitis.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2015
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00835848
Start Date
January 1 2009
End Date
May 1 2015
Last Update
May 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart Center, Rigshospitalet
Copenhagen, Denmark, 2100